The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period - ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.5, a high estimate of $30.00, and a low estimate of $22.00. This upward trend is apparent, ...

The U.S. Food and Drug Administration has already awarded zorevunersen (also known as STK-001) with breakthrough therapy designation for treating Dravet syndrome. Jefferies highlighted that investors ...

According to Jefferies, Phase I/II open-label data suggests zorevunersen can reduce seizures by month six of treatment and improve cognitive and behavioral measures by month nine, indicating ...

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

Reports Q2 revenue $13.8M, consensus $5.2M. “This quarter was defined by strong execution that is driving momentum across our business,” said Ian ...

Recognized for its potential, zorevunersen has received FDA Breakthrough Therapy Designation, as well as orphan drug and rare pediatric disease designations.